ArticleScientific reports2025
Synthesis, structural elucidation, and molecular docking of diclofenac-derived hydrazone metal complexes with anti-inflammatory and anticancer potential.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Design, Synthesis, and Bioevaluation of Moxifloxacin Hydrazide Metal Complexes: Integrated Spectroscopic, Computational, Antimicrobial, and Anticancer Investigations.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel Schiff base ligand, (E)-2-(2-((2,6-dichlorophenyl)amino)phenyl)-N'-(2-hydroxynaphthalen-1-yl)methylene)acetohydrazide, was synthesized and complexed with Cu(II), Ni(II), Co(II), Gd(III), La(III), and Ag(I) ions. The resulting metal complexes were characterized using FTIR, UV-Vis, 1H NMR, ESR, XRD, thermal analysis, and magnetic susceptibility measurements. Spectroscopic and magnetic data confirmed octahedral geometries for Co(II), Ni(II), and Cu(II), square antiprismatic and tricapped trigonal prismatic geometries for Gd(III) and La(III), respectively, and a tetrahedral geometry for Ag(I). The anti-inflammatory activity was evaluated using ELISA-based COX-1/COX-2 inhibition assays. The HDN ligand exhibited potent COX-2 inhibition (IC₅₀ = 0.06 µM) with a selectivity index (SI) of 174.5, outperforming diclofenac sodium (SI = 4.52) and indomethacin (SI = 1.25), and approaching rofecoxib (SI = 725). The Cu(II) and Gd(III) complexes showed strong cytotoxicity in MTT assays against MCF-7 (IC₅₀ = 0.65 and 0.80 µM) and HepG-2 (IC₅₀ = 1.00 and 2.47 µM) cell lines, significantly surpassing the HDN ligand and standard drugs such as 5-fluorouracil (IC₅₀ = 3.95 µM, MCF-7) and cisplatin (IC₅₀ = 15.24 µM, MCF-7). In silico studies including molecular docking and ADME profiling supported the experimental findings. The HDN ligand and Cu(II) complex exhibited strong binding affinities to COX-2 (- 22.87 kcal/mol), HepG-2 (- 32.56 and - 31.76 kcal/mol), and MCF-7 (- 25.29 and - 20.20 kcal/mol) receptors. SwissADME and BOILED-Egg models predicted high gastrointestinal absorption for the HDN ligand and favorable pharmacokinetic profiles for the metal complexes. The present results provide a preclinical proof-of-concept for diclofenac-derived Schiff base metal complexes as dual anti-inflammatory and anticancer agents. However, their therapeutic potential remains to be validated through stability, mechanistic, and in vivo investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.